Novel medical strategies in acute severe ulcerative colitis (notice n° 1810425)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01937cam a2200193 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260329001956.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Calméjane, Louis |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Novel medical strategies in acute severe ulcerative colitis |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 61 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Acute severe ulcerative colitis occurs in up to 25% of patients with ulcerative colitis (UC). Therapeutic approaches have evolved in recent years with an increase in the use of biotherapies and in the number of treatments approved for moderate-to-severe UC. In this review, we summarize the latest evidence regarding short- and long-term medical strategies for severe acute colitis. In addition to standard care procedures—such as venous thromboembolism (VTE) prophylaxis, screening for triggers and aggravating factors, and close monitoring—the first-line treatment for severe acute colitis remains intravenous corticosteroids. Second-line therapies include infliximab and ciclosporin, which have similar short- and long-term colectomy rates. Pre-treatment exposure is key to guiding the choice of short- and long-term therapies in the context of severe acute colitis: In patients exposed to anti-TNF, calcineurin inhibitors may be preferred as a bridge therapy to vedolizumab or ustekinumab. Increasing evidence also supports the use of tofacitinib and anti-JAK in severe acute colitis. Finally, we will present future therapeutic perspectives, including novel combination therapies. A visual abstract summarizing these medical strategies is provided with this review. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Laharie, David |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kirchgesner, Julien |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Uzzan, Mathieu |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 31 | 3 | 2024-03-01 | p. 333-341 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2024-3-page-333?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2024-3-page-333?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux